These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
741 related items for PubMed ID: 21684478
1. Paraoxonase-1 activity, malondialdehyde and glutathione peroxidase in non-alcoholic fatty liver disease and the effect of atorvastatin. Samy W, Hassanian MA. Arab J Gastroenterol; 2011 Jun; 12(2):80-5. PubMed ID: 21684478 [Abstract] [Full Text] [Related]
3. A new marker for lipid peroxidation: serum paraoxonase activity in non-alcoholic steatohepatitis. Başkol M, Başkol G, Deniz K, Ozbakir O, Yücesoy M. Turk J Gastroenterol; 2005 Sep; 16(3):119-23. PubMed ID: 16245219 [Abstract] [Full Text] [Related]
6. [Investigation of oxidative stress and antioxidant defense in patients with hepatitis B virus infection and the effect of interferon-alpha plus lamivudine combination therapy on oxidative stress]. Acar A, Görenek L, Aydin A, Eyigün CP, Eken A, Sayal A, Pahsa A. Mikrobiyol Bul; 2009 Jul; 43(3):411-23. PubMed ID: 19795616 [Abstract] [Full Text] [Related]
9. The effect of atorvastatin therapy on lecithin:cholesterol acyltransferase, cholesteryl ester transfer protein and the antioxidant paraoxonase. Kassai A, Illyés L, Mirdamadi HZ, Seres I, Kalmár T, Audikovszky M, Paragh G. Clin Biochem; 2007 Jan; 40(1-2):1-5. PubMed ID: 16999950 [Abstract] [Full Text] [Related]
11. A pilot study of atorvastatin treatment in dyslipemid, non-alcoholic fatty liver patients. Gómez-Domínguez E, Gisbert JP, Moreno-Monteagudo JA, García-Buey L, Moreno-Otero R. Aliment Pharmacol Ther; 2006 Jun 01; 23(11):1643-7. PubMed ID: 16696815 [Abstract] [Full Text] [Related]
12. Preventive role of genistein in an experimental non-alcoholic steatohepatitis model. Yalniz M, Bahcecioglu IH, Kuzu N, Poyrazoglu OK, Bulmus O, Celebi S, Ustundag B, Ozercan IH, Sahin K. J Gastroenterol Hepatol; 2007 Nov 01; 22(11):2009-14. PubMed ID: 17914984 [Abstract] [Full Text] [Related]
13. Effects of atorvastatin and omega-3 fatty acids on LDL subfractions and postprandial hyperlipemia in patients with combined hyperlipemia. Nordøy A, Hansen JB, Brox J, Svensson B. Nutr Metab Cardiovasc Dis; 2001 Feb 01; 11(1):7-16. PubMed ID: 11383326 [Abstract] [Full Text] [Related]
14. Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia. Hyogo H, Tazuma S, Arihiro K, Iwamoto K, Nabeshima Y, Inoue M, Ishitobi T, Nonaka M, Chayama K. Metabolism; 2008 Dec 01; 57(12):1711-8. PubMed ID: 19013295 [Abstract] [Full Text] [Related]
16. Effect of atorvastatin on paraoxonase1 (PON1) and oxidative status. Nagila A, Permpongpaiboon T, Tantrarongroj S, Porapakkham P, Chinwattana K, Deakin S, Porntadavity S. Pharmacol Rep; 2009 Dec 01; 61(5):892-8. PubMed ID: 19904013 [Abstract] [Full Text] [Related]
17. Assessment of the efficacy and tolerability of a fixed dose combination of atorvastatin 10 mg + metformin SR 500 mg in diabetic dyslipidaemia in adult Indian patients. Balasubramanian R, Varadharajan S, Kathale A, Nagraj LM, Periyandavar I, Nayak UP, Sharma A, Bolmall C, Baliga VP. J Indian Med Assoc; 2008 Jul 01; 106(7):464-7. PubMed ID: 18975505 [Abstract] [Full Text] [Related]
19. Assessment of paraoxonase activity and lipid peroxidation levels in diabetic and senile subjects suffering from cataract. Hashim Z, Zarina S. Clin Biochem; 2007 Jun 01; 40(9-10):705-9. PubMed ID: 17466963 [Abstract] [Full Text] [Related]